Sponsor Dossier
Juno Pharmaceuticals
Sponsor Dossier for Juno Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ADENOSINE
- Brand: ADRENALINE
- Brand: AMIODARONE
- Brand: AMOXICLAV JUNO
- Brand: ANIDULAFUNGIN
- Brand: APO-PALONOSETRON
- Brand: ARSENIC
- Brand: ATROPINE JUNO
- Device (sponsor): Syringe-loaded injector, manual, home-use
- Device (sponsor): IALURIL Procedure pack - Bladder instillation, barrier
- Device (sponsor): Urethral intravesical infusion tip
- Device (sponsor): IALURIL Prefill - Bladder instillation, barrier
- Device (sponsor): Adaptor, luer
About
Juno Pharmaceuticals is an Australian Private Company with ABN 55156303650, registered in Victoria. The entity is active and registered for GST from 2012.
Portfolio
Juno Pharmaceuticals has 99 brands on the ARTG, of which 70 are indexable and 63 carry a Product Information document. 28 brands are PBS-listed, 7 have a PBAC outcome on record, and 1 has an AusPAR on record. Notable brands include ADENOSINE, ADRENALINE, AMIODARONE, AMOXICLAV JUNO, ANIDULAFUNGIN, APO-PALONOSETRON, ARSENIC, ATROPINE JUNO, AZACITIDINE, BENDAMUSTINE JUNO, BIVALIRUDIN, BLEO.
Therapeutic focus
— Infectious Disease: 23 brands — Oncology: 19 brands — Pain Management: 16 brands — Cardiology: 13 brands — Neurology: 6 brands — Haematology: 5 brands — Other: 4 brands — Endocrinology: 4 brands — Musculoskeletal: 3 brands — Psychiatry: 2 brands — Gastroenterology: 2 brands — Reproductive Health: 1 brand — Ophthalmology: 1 brand
PBS footprint
28 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2025-07-01, across 7 brands with a PBAC outcome on record. The latest AusPAR is 2024-03-04, across 1 brand with an AusPAR on record.